通过EuroGTP II风险评估工具评估新型生殖技术与疗法的风险、安全性和有效性
该研究基于EuroGTP II通用风险评估算法,经八位辅助生殖技术专家四次会议及多项测试模拟,开发了辅助生殖技术专用风险评估工具EuroGTP II-ART。工具涵盖新颖性评估、潜在风险与后果识别及风险评分、风险降低策略与扩展研究定义三步,并针对性腺组织增加潜在风险。
要点
- EuroGTP II-ART工具可系统结构化评估辅助生殖技术新颖性的风险。
- 工具三步:新颖性评估七问、风险与后果识别及评分、风险降低策略与扩展研究定义。
- 风险评估需多学科团队完成,并需解读结果以确定风险缓解策略和下一步措施。
核心结论
- 已开发出辅助生殖技术专用风险评估工具EuroGTP II-ART,可系统结构化评估辅助生殖技术新颖性的风险。
- 该工具为动态工具,其价值不仅在于临床实践前评估风险,还在于根据过程中收集的信息重新评估风险。
研究设计与样本
- 基于为组织与细胞疗法及产品开发的通用风险评估算法,在EuroGTP II项目背景下开发。
- 共举行四次会议,八位辅助生殖技术专家参与,并开展多项测试与模拟以微调最终工具。
- 对EuroGTP II方法学三个步骤在辅助生殖技术中的实用性和适用性进行了评估。
主要发现
- 步骤1新颖性评估含七个问题,与其他组织与细胞疗法及产品相同,并附实际示例以便理解。
- 步骤2潜在风险与后果识别经改编,增加了涉及性腺组织过程的潜在风险,风险评分算法亦经改编并给出最高可能风险评分的特定范围。
- 步骤3风险降低策略清单及确保有效性和安全性所需扩展研究的定义由辅助生殖技术专家基于通用EuroGTP II方法学制定。
- 每个步骤均提供解释和示例,以便在该领域内更好理解。
临床怎么用
- 风险评估需多学科团队执行,以解读结果并确定风险缓解策略和/或确保新颖性临床使用安全所需的下一步措施。
- 该工具可在实施新型辅助生殖技术前用于风险评估,并可根据过程中收集的信息重新评估风险。
局限性
- 风险评估需多学科团队执行,以解读结果并确定风险缓解策略和/或确保新颖性临床使用安全所需的下一步措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can risks associated with novelties in assisted reproduction technologies (ARTs) be assessed in a systematic and structured way? SUMMARY ANSWER: An ART-specific risk assessment tool has been developed to assess the risks associated with the development of novelties in ART (EuroGTP II-ART). WHAT IS KNOWN ALREADY: How to implement new technologies in ART is well-described in the literature. The successive steps should include testing in animal models, executing pre-clinical studies using supernumerary gametes or embryos, prospective clinical trials and finally, short- and long-term follow-up studies on the health of the offspring. A framework categorizing treatments from experimental through innovative to established according to the extent of the studies conducted has been devised. However, a systematic and standardized methodology to facilitate risk evaluation before innovations are performed in a clinical setting is lacking. STUDY DESIGN, SIZE, DURATION: The EuroGTP II-ART risk assessment tool was developed on the basis of a generic risk assessment algorithm developed for tissue and cell therapies and products (TCTPs) in the context of the project 'Good Practices for demonstrating safety and quality through recipient follow-up European Good Tissue and cells Practices II (EuroGTP II)'. For this purpose, a series of four meetings was held in which eight ART experts participated. In addition, several tests and simulations were undertaken to fine-tune the final tool. PARTICIPANTS/MATERIALS, SETTING, METHODS: The three steps comprising the EuroGTP II methodology were evaluated against its usefulness and applicability in ART. Ways to improve and adapt the methodology into ART risk assessment were agreed and implemented. MAIN RESULTS AND THE ROLE OF CHANCE: Assessment of the novelty (Step 1), consisting of seven questions, is the same as for other TCTPs. Practical examples were included for better understanding. Identification of potential risks and consequences (Step 2), consisting of a series of risks and risk consequences to consider during risk assessment, was adapted from the generic methodology, adding more potential risks for processes involving gonadic tissues. The algorithm to score risks was also adapted, giving a specific range of highest possible risk scores. A list of strategies for risk reduction and definition of extended studies required to ensure effectiveness and safety (Step 3) was also produced by the ART experts, based on generic EuroGTP II methodology. Several explanations and examples were provided for each of the steps for better understanding within this field. LIMITATIONS, REASONS FOR CAUTION: A multidisciplinary team is needed to perform risk assessment, to interpret results and to determine risk mitigation strategies and/or next steps required to ensure the safety in the clinical use of novelties. WIDER IMPLICATIONS OF THE FINDINGS: This is a dynamic tool whose value goes beyond assessment of risk before implementing a novel ART in clinical practice, to re-evaluate risks based on information collected during the process. STUDY FUNDING / COMPETING INTEREST(S): This study was called EUROGTP II and was funded by the European Commission (Grant agreement number 709567). The authors declare no competing interests concerning the results of this study.
引用
- Trias E, Nijs M, Rugescu IA, et al. Evaluating risk, safety and efficacy of novel reproductive techniques and therapies through the EuroGTP II risk assessment tool. Hum Reprod. 2020. PMID: 32728714. doi:10.1093/humrep/deaa146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。